AtriCure, Inc. (NASDAQ:ATRC) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC grew its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 12.8% during the second quarter, HoldingsChannel reports. The institutional investor owned 171,700 shares of the medical device company’s stock after buying an additional 19,500 shares during the quarter. Renaissance Technologies LLC’s holdings in AtriCure were worth $3,910,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Comerica Bank increased its holdings in shares of AtriCure by 70.5% during the first quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock valued at $77,000 after purchasing an additional 1,043 shares during the period. Quest Partners LLC lifted its position in AtriCure by 38.3% in the second quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock worth $134,000 after purchasing an additional 1,626 shares during the period. Virtu Financial LLC bought a new position in AtriCure during the 4th quarter valued at $213,000. Mount Yale Investment Advisors LLC bought a new position in AtriCure during the 1st quarter valued at $224,000. Finally, ProShare Advisors LLC increased its position in shares of AtriCure by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 8,371 shares of the medical device company’s stock valued at $255,000 after purchasing an additional 659 shares during the period. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Down 0.8 %

ATRC opened at $28.18 on Friday. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $44.64. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.93 and a current ratio of 4.13. The business has a 50 day moving average price of $24.98 and a 200 day moving average price of $24.52. The firm has a market cap of $1.34 billion, a P/E ratio of -35.23 and a beta of 1.43.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Tuesday, July 30th. The medical device company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). AtriCure had a negative return on equity of 8.39% and a negative net margin of 9.33%. The business had revenue of $116.27 million for the quarter, compared to the consensus estimate of $116.24 million. During the same quarter last year, the business posted ($0.12) EPS. The firm’s revenue was up 15.2% compared to the same quarter last year. Research analysts forecast that AtriCure, Inc. will post -0.77 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ATRC shares. StockNews.com upgraded AtriCure from a “sell” rating to a “hold” rating in a report on Saturday, September 14th. BTIG Research cut their price target on shares of AtriCure from $58.00 to $53.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Needham & Company LLC cut their target price on shares of AtriCure from $40.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Piper Sandler decreased their price target on shares of AtriCure from $65.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. reduced their price objective on AtriCure from $34.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.44.

Insider Buying and Selling

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $24.07, for a total value of $84,245.00. Following the completion of the transaction, the director now directly owns 8,970 shares in the company, valued at $215,907.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.20% of the stock is currently owned by corporate insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.